Nordea Investment Management
PTGX icon

Nordea Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Nordea Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.94M Buy
64,964
+13,143
+25% +$1.37M 0.01% 501
2026
Q1 		$5.33M Buy
+51,821
New +$4.59M 0.01% 565

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Nordea Investment Management's PTGX Position: Q2 2026 in Review

Nordea Investment Management increased its Protagonist Therapeutics (PTGX) stake by 25% in Q2 2026, buying an estimated $1.37M and bringing the position to 64,964 shares worth $7.94M. The position accounts for 0.01% of the portfolio, ranked #501.

Nordea Investment Management first reported a position in PTGX in Q1 2026 and has held it in 2 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Nordea Investment Management held 64,964 shares of Protagonist Therapeutics worth $7.94M as of Q2 2026.
  • Nordea Investment Management bought 13,143 Protagonist Therapeutics shares in Q2 2026, an estimated $1.37M.
  • Protagonist Therapeutics made up 0.01% of Nordea Investment Management's portfolio in Q2 2026, its #501 holding.
  • Nordea Investment Management first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Nordea Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.